2,683 reports of this reaction
2.7% of all MIRABEGRON reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for MIRABEGRON, manufactured by Astellas Pharma US, Inc.. There are 2,683 FDA adverse event reports linking MIRABEGRON to OFF LABEL USE. This represents approximately 2.7% of all 99,871 adverse event reports for this drug.
MIRABEGRON has an overall safety score of 78 out of 100. Patients taking MIRABEGRON who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for MIRABEGRON, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for MIRABEGRON:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 2,683 FDA reports for MIRABEGRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.7% of all adverse event reports for MIRABEGRON, making it one of the most commonly reported side effect.
If you experience off label use while taking MIRABEGRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.